History
The Jewish General Hospital (JGH) Clinical Research Program (CRP) in Montreal stands at the forefront of oncology research, conducting state-of-the-art clinical trials that advance our understanding of cancer treatments and improve patient outcomes. Since its establishment in 2016, the program has successfully launched more than 250 clinical trials through strategic partnerships with leading research organizations, including the Canadian Cancer Trials Group (CCTG), numerous multi-national pharmaceutical companies, NRG Oncology, and various cooperative research groups. The program maintains a robust portfolio focused primarily on late-stage clinical development, specifically Phase IIb, III, and IV trials, while also pioneering innovative Phase I radioligand studies in close collaboration with the Division of Nuclear Medicine at the JGH.
Disease Sites
The CRP maintains a comprehensive portfolio across multiple disease sites, with particular expertise in breast and prostate cancer research spanning the entire treatment continuum. A distinguishing feature of the prostate cancer portfolio is its innovative work in theranostics and radioligand therapies. Additionally, the program has developed specialized expertise in neuroendocrine tumors (NET), further diversifying its research capabilities and contributing to advanced treatment options for patients with these rare malignancies.
Breast Cancer
Prostate Cancer
Lung Cancer
Colorectal Cancer
Pancreatic Cancer
Urothelial Cancer
Neuroendocrine Tumors
Endometrial Cancer
Gastroesophageal Cancer
Ovarian Cancer
Lymphoma
Multiple Myeloma
And many others...
​​​
​
Principle Investigators
Dr. Jason Agulnik
Dr. Parvaneh Fallah
Dr. Cristiano Ferrario
Dr. Nathalie Johnson
Dr. Rayan Kaedbey
Dr. Petr Kavan
Dr. Kim Ma
Dr. April Rose
Dr. Tanya Skamene
Staff Overview
The CRP is powered by a dedicated team of 29 highly skilled professionals under the exemplary leadership of Managing Director Dr. Aline Mamo, PhD.
​
The program's comprehensive staffing structure reflects its commitment to maintaining rigorous research standards while prioritizing patient safety and data integrity. The core research operations are supported by three Research Ethics Coordinators who work closely with two Regulatory Coordinators to ensure all trials meet stringent ethical and regulatory requirements. Clinical oversight is provided by two experienced Clinical Research Nurses who work alongside nine Study Coordinators to manage day-to-day trial operations and patient care.
​
The program's robust data management and quality assurance framework is maintained by four Clinical Data Managers, two Quality Control Officers, and two Safety Officers who collectively ensure the accuracy and reliability of research data while monitoring patient safety. Supporting the program's laboratory requirements are two Laboratory Assistants who handle critical specimen processing and management. The financial aspects of clinical trials are expertly managed by two Financial Coordinators who oversee budgeting, contracting, and financial compliance.
This well-structured team has been instrumental in the program's success in conducting complex oncology trials and advancing cancer research.
Capabilities
The CRP benefits from its association with the JGH Segal Cancer Center, a hub for cutting-edge oncology research, combining state-of-the-art resources with unparalleled expertise. Led by highly experienced principal investigators and a dedicated research team, the CRP excels in theranostics, radioligands, radiation dosimetry, and leveraging advanced imaging modalities such as MRI, CT, PET/CT, and SPECT/CT.
The unit specializes in conducting molecular profiling cohorts using next-generation sequencing (NGS), liquid biopsies, and correlative studies to uncover novel insights. With extensive experience in managing complex toxicities and fostering strong academic and pharmaceutical partnerships, the CRP delivers innovative solutions and accelerates the translation of research into impactful cancer therapies.